全文获取类型
收费全文 | 36597篇 |
免费 | 2528篇 |
国内免费 | 778篇 |
专业分类
耳鼻咽喉 | 234篇 |
儿科学 | 1138篇 |
妇产科学 | 233篇 |
基础医学 | 1884篇 |
口腔科学 | 1247篇 |
临床医学 | 6052篇 |
内科学 | 13205篇 |
皮肤病学 | 83篇 |
神经病学 | 755篇 |
特种医学 | 1290篇 |
外科学 | 4947篇 |
综合类 | 5151篇 |
一般理论 | 1篇 |
预防医学 | 790篇 |
眼科学 | 286篇 |
药学 | 1836篇 |
18篇 | |
中国医学 | 605篇 |
肿瘤学 | 148篇 |
出版年
2024年 | 27篇 |
2023年 | 618篇 |
2022年 | 729篇 |
2021年 | 1298篇 |
2020年 | 1409篇 |
2019年 | 1368篇 |
2018年 | 1298篇 |
2017年 | 962篇 |
2016年 | 844篇 |
2015年 | 1026篇 |
2014年 | 2450篇 |
2013年 | 2133篇 |
2012年 | 1698篇 |
2011年 | 2036篇 |
2010年 | 1782篇 |
2009年 | 1658篇 |
2008年 | 1782篇 |
2007年 | 1903篇 |
2006年 | 1631篇 |
2005年 | 1613篇 |
2004年 | 1298篇 |
2003年 | 1096篇 |
2002年 | 974篇 |
2001年 | 917篇 |
2000年 | 739篇 |
1999年 | 732篇 |
1998年 | 636篇 |
1997年 | 635篇 |
1996年 | 506篇 |
1995年 | 472篇 |
1994年 | 433篇 |
1993年 | 369篇 |
1992年 | 372篇 |
1991年 | 315篇 |
1990年 | 275篇 |
1989年 | 207篇 |
1988年 | 202篇 |
1987年 | 209篇 |
1986年 | 193篇 |
1985年 | 196篇 |
1984年 | 188篇 |
1983年 | 131篇 |
1982年 | 138篇 |
1981年 | 99篇 |
1980年 | 80篇 |
1979年 | 73篇 |
1978年 | 49篇 |
1977年 | 24篇 |
1976年 | 28篇 |
1975年 | 17篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
《Saudi Pharmaceutical Journal》2022,30(6):669-678
BackgroundIschemia reperfusion (I/R) play an imperative role in the expansion of cardiovascular disease. Sinomenine (SM) has been exhibited to possess antioxidant, anticancer, anti-inflammatory, antiviral and anticarcinogenic properties. The aim of the study was scrutinized the cardioprotective effect of SM against I/R injury in rat.MethodsRat were randomly divided into normal control (NC), I/R control and I/R + SM (5, 10 and 20 mg/kg), respectively. Ventricular arrhythmias, body weight and heart weight were estimated. Antioxidant, inflammatory cytokines, inflammatory mediators and plasmin system indicator were accessed.ResultsPre-treated SM group rats exhibited the reduction in the duration and incidence of ventricular fibrillation, ventricular ectopic beat (VEB) and ventricular tachycardia along with suppression of arrhythmia score during the ischemia (30 and 120 min). SM treated rats significantly (P < 0.001) altered the level of antioxidant parameters. SM treatment significantly (P < 0.001) repressed the level of creatine kinase MB (CK-MB), creatine kinase (CK) and troponin I (Tnl). SM treated rats significantly (P < 0.001) repressed the tissue factor (TF), thromboxane B2 (TXB2), plasminogen activator inhibitor 1 (PAI-1) and plasma fibrinogen (Fbg) and inflammatory cytokines and inflammatory mediators.ConclusionOur result clearly indicated that SM plays anti-arrhythmia effect in I/R injury in the rats via alteration of oxidative stress and inflammatory reaction. 相似文献
2.
目的探讨顺行指掌侧固有动脉推进皮瓣应用于指端组织缺损患者的疗效。方法77例指端组织缺损患者随机分为两组,对照组行指动脉逆行岛状皮瓣修复术,实验组行顺行指掌侧固有动脉推进皮瓣修复术,比较两组的疗效、术后患指功能以及并发症。结果实验组的治疗优良率和术后患指功能评分均显著高于对照组(P<0.05);两组的术后并发症发生率无统计学差异(P>0.05)。结论顺行指掌侧固有动脉推进皮瓣在指端组织缺损患者中应用效果显著,可促进术后患指功能恢复,安全性高。 相似文献
3.
4.
《Revista portuguesa de cardiologia》2022,41(3):253-259
Left ventricular noncompaction (LVNC) is a genetically heterogeneous cardiomyopathy, with familial and sporadic forms, but genetic testing only identifies a pathogenic mutation in a minority of cases. The main complications are heart failure, embolism and dysrhythmias. Herein we report a familial case of LVNC associated with a mutation in the MYH7 gene and review the literature regarding controversies in LVNC. A 50-year-old woman was referred to the cardiology clinic for palpitations. She underwent echocardiography and cardiac magnetic resonance imaging that revealed mild left ventricular systolic dysfunction and LVNC criteria. She had several episodes of non-sustained ventricular tachycardia and received an implantable cardioverter-defibrillator (ICD). Genetic testing revealed the c.1003G>C (p.Ala335Pro) mutation in the MYH7 gene. Familial screening showed clear genotype-phenotype cosegregation, which provided strong evidence for the pathogenic role of this mutation. To the best of our knowledge, this is the first report of LVNC associated with the p.Ala335Pro mutation in the MYH7 gene. This mutation has been described in hypertrophic cardiomyopathy, suggesting that the same pathogenic sarcomere mutation may be associated with different cardiomyopathies. This case also highlights the current difficulties regarding decisions on ICD implantation for primary prevention of sudden cardiac death in LVNC. 相似文献
5.
6.
7.
8.
9.
BackgroundAdvanced oral tongue carcinoma can present with extension beyond the oral cavity. Operative defects after resection may involve multiple anatomical sites and significantly impact speech and swallowing. Dependence on long-term enteral feeding is not uncommon for these patients. The anterolateral thigh (ALT) flap is one of the most reliable and flexible flaps used in the reconstruction of total and subtotal tongue defects. The double-paddle flap modification may be a more suitable option for complex oral tongue defects after advanced tumor ablation.MethodsCase series of 31 patients with oral tongue squamous cell carcinoma that were classified as stage IV. The age of patients ranged from 32 to 63 years. We designed the double-paddle ALT flaps to reconstruct the two-site surgical defects (tongue defect and pharynx or neck skin defect). Postoperative viability of the flap was checked by clinical observation. The last examination was performed at 3-months after the completion of adjuvant chemoradiotherapy. The functional capacity of our patients was evaluated by three physicians (Head and Neck Surgeon, Radiation Oncologist, and Physiatrist) using a Speech Intelligibility Score and the Functional Oral Intake Scale.ResultsA total of 31 patients with surgical defects after total or subtotal tongue resection for cancer underwent double-paddle ALT flaps for reconstruction from March 2018 to December 2019. The dimension of flaps from 8 × 12 cm to 10 × 18 cm were divided into double-paddle from 8 × 5 cm to 10 × 10 cm. There was one case of pedicle thrombosis, one case of postoperative bleeding, three cases of neck infection, and six cases of salivary fistula. Our patients were seen in follow up from 6 to 36 months, with median follow-up of 23.5 months. The survival rate of ALT flap was 100%. All of our patients achieved an oral diet by 9 months after surgery. The mean score speech intelligibility was 2.74 ± 0.68 (4-point ordinal scale). The 2-year disease-free survival rate was 61.3%.ConclusionsThe double-paddle ALT flap is a reliable flap suitable for oral defects involving multiple subsites after ablative procedures. The majority of patients demonstrated acceptable functional rehabilitation.Clinical question/ level of evidenceTherapeutic, IV. 相似文献
10.
《The Journal of thoracic and cardiovascular surgery》2023,165(1):149-158.e4
BackgroundCoronary artery bypass grafting (CABG) improves survival in patients with heart failure and severely reduced left ventricular systolic function (LVEF). Limited data exist regarding adverse cardiovascular event rates after CABG in patients with heart failure with midrange ejection fraction (HFmrEF; LVEF > 40% and < 55%).MethodsWe analyzed data on isolated CABG patients from the Veterans Affairs national database (2010-2019). We stratified patients into control (normal LVEF and no heart failure), HFmrEF, and heart failure with reduced LVEF (HFrEF) groups. We compared all-cause mortality and heart failure hospitalization rates between groups with a Cox model and recurrent events analysis, respectively.ResultsIn 6533 veterans, HFmrEF and HFrEF was present in 1715 (26.3%) and 566 (8.6%) respectively; the control group had 4252 (65.1%) patients. HFrEF patients were more likely to have diabetes mellitus (59%), insulin therapy (36%), and previous myocardial infarction (31%). Anemia was more prevalent in patients with HFrEF (49%) as was a lower serum albumin (mean, 3.6 mg/dL). Compared with the control group, a higher risk of death was observed in the HFmrEF (hazard ratio [HR], 1.3 [1.2-1.5)] and HFrEF (HR, 1.5 [1.2-1.7]) groups. HFmrEF patients had the higher risk of myocardial infarction (subdistribution HR, 1.2 [1-1.6]; P = .04). Risk of heart failure hospitalization was higher in patients with HFmrEF (HR, 4.1 [3.5-4.7]) and patients with HFrEF (HR, 7.2 [6.2-8.5]).ConclusionsHeart failure with midrange ejection fraction negatively affects survival after CABG. These patients also experience higher rates myocardial infarction and heart failure hospitalization. 相似文献